CSL Group publishes its annual report for 2020-21 To find out more, visit CSL.com CSL Behring France reveals its excellent results on the professional equality index between women and men CSL Behring announces global agreement with UniQure Our commitment to rare diseases Our portfolio of innovative drugs includes a wide range of recombinant and plasma-derived products for the treatment of coagulation disorders, immune deficiencies, and autoimmune and inflammatory diseases, as well as for hereditary angioedema and deficiency. alpha-1 antitrypsin. Read more Contribute to our future Join a global leader in biotechnology. We are waiting for you ! Learn more about career opportunities at CSL Behring Our products Discover the products we offer here. Find out more Career opportunities Rejoignez-nous et faites la différence en travaillant avec des professionnels compétents et passionnés. En savoir plus Notre actualité Découvrez toute l’actualité de CSL Behring. En savoir plus FR/INS/18-0006 - Octobre 2018 CSL Behring © 2021 Conditions d'utilisation Politique de confidentialité Charte cookies Plan du site By clicking on "Accept all cookies", you agree to the storage of cookies on your device to improve site navigation, analyze its use and contribute to our marketing efforts. Cookie settings Refuse everything Allow all cookies